Recent studies have shown that treatment of CRC with EGFR inhibitors is more likely to lead to KRAS/BRAF mutations compared to general cytotoxic chemotherapy, suggesting that mutations in these key proteins should be expected when treating patients, further amplifying the need for alternative and combination therapies [42]. The gene discussed is KRAS; the disease is colorectal carcinoma.